Research on Multiple Sclerosis Reported by Researchers at University of Colorado (Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis).

Researchers at the University of Colorado conducted phase 3 studies comparing the effectiveness of ublituximab and teriflunomide in treating relapsing multiple sclerosis. The results showed significant improvements in annualized relapse rate, lesion numbers, and no evidence of disease activity with ublituximab compared to teriflunomide. The study concluded that ublituximab consistently provided better outcomes across different participant subpopulations. This research offers valuable insights into potential treatment options for individuals with multiple sclerosis. [Extracted from the article]